Description:
Rolimus^® is a preparation of Tacrolimus which works as an immunosuppressant. It is for topical dermatologic use only.

Indications:
Rolimus^® ointment is indicated for short-term and intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. Rolimus^® Ointment is also indicated in other skin conditions such as chronic cutaneous graft-vs-host disease, hand and foot eczema, allergic contact dermatitis, psoriasis, lichen planus, facial lichen, vulvar lichen sclerosis, pyoderma gangrenosum, leg ulcers in rheumatoid arthritis, steroid-induced rosacea & alopecia areata, annular erythema, chronic actinic dermatitis and recalcitrant facial erythema.

Mode of Action:
The exact mechanism of action of Tacrolimus is not known. It has been demonstrated that Tacrolimus inhibits T-lymphocyte activation by binding to an intracellular protein, FKBP-12. A complex of Tacrolimus-FKBP-12, Calcium, Calmodulin and Calcineurin is then formed and the phosphatase activity of Calcineurin inhibited. This effect may prevent the dephosphorylation and translocation of nuclear factor of activated T-cells. Tacrolimus prolongs the survival of the host and transplanted graft in animal transplant models of liver, kidney, heart, bone marrow, small bowel and pancreas, lung and trachea, skin, cornea, and limb.

View Details